Esophageal Diseases  >>  rilotumumab (AMG 102)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
rilotumumab (AMG 102) / Amgen
NCT00719550 / 2008-001605-42: AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer

Checkmark As 1st line treatment for gastric/oesophagogastric junction adenocarcinoma
Jun 2014 - Jun 2014: As 1st line treatment for gastric/oesophagogastric junction adenocarcinoma
Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Checkmark
More
Completed
1b/2
130
US, Canada, Europe, RoW
Capecitabine, Xeloda, Epirubicin, AMG 102, Cisplatin, Placebo
Amgen
Esophagogastric Junction Adenocarcinoma, Gastric Cancer, Esophageal Cancer
11/10
06/13

Download Options